Pain After Cardiac Arrest and Resuscitation (PAINCARE) (PAINCARE)
11 de mayo de 2026 actualizado por: Joachim Düring, Region Skane
Characterizing and Quantifying Pain After Cardiac Arrest and Resuscitation: Insights From the PAINCARE Substudy of the STEPCARE Trial
The PAINCARE substudy is an observational cohort substudy nested within the international STEPCARE trial, which evaluates sedation, temperature, and mean arterial pressure strategies after out-of-hospital cardiac arrest.
PAINCARE aims to describe the burden of pain during early intensive care after cardiac arrest and to evaluate associations between early pain burden and selected ICU and patient-reported outcomes.
Pain is common in critically ill patients but may be difficult to assess in patients who are unconscious, sedated, mechanically ventilated, or unable to self-report.
PAINCARE collects structured pain assessments during the first 168 hours after randomization using validated self-report or behavioral pain instruments and relates early pain burden to outcomes including delirium burden, ventilator-free time, ICU-free time, and follow-up pain outcomes.
All analyses are observational; PAINCARE is not designed to determine whether modifying pain burden improves outcomes.
Descripción general del estudio
Estado
Estado
Reclutamiento
Condiciones
Condiciones
Descripción detallada
PAINCARE is an exploratory observational substudy.
The available sample size is expected to be approximately 300 participants and will be determined by PAINCARE participation, consent status, availability of PAINCARE data, and eligibility for the relevant analysis population.
The primary analysis will estimate cumulative time in moderate/severe pain while alive and in the ICU from randomization through 168 hours, ICU discharge, or death, whichever occurs first.
Secondary analyses will evaluate associations between early pain burden and selected ICU and patient-reported outcomes.
Missingness will be reported by variable, timepoint, site, and ascertainment mode where feasible.
Prespecified analysis rules distinguish missing scorable intervals from non-scorable intervals, allow deterministic imputation only for isolated missing scorable intervals meeting prespecified criteria, and use endpoint-specific analysis populations for secondary and exploratory analyses.
Sensitivity analyses will assess robustness to assumptions about pain-data completeness, deterministic imputation, non-scorable intervals, pain-state thresholds, and ascertainment mode.
Analyses will be primarily descriptive and associational; findings outside the primary analysis will be considered hypothesis-generating.
PAINCARE includes both retrospectively and prospectively ascertained participants according to local approvals and substudy implementation.
Tipo de estudio
Tipo de estudio
De observación
Inscripción (Estimado)
Inscripción
300
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
Estudio Contacto
- Nombre: Joachim P Düring, MD, PhD
- Número de teléfono: +46705917599
- Correo electrónico: joachim.during@med.lu.se
Copia de seguridad de contactos de estudio
- Nombre: Mia H Hylén, RN, PhD
- Número de teléfono: +46708277226
- Correo electrónico: mia.hylen@skane.se
Ubicaciones de estudio
-
-
-
Halmstad, Suecia
- Reclutamiento
- Dep. of Intensive Care Halmstad Lasarett
-
Contacto:
- Johan Undén, MD, PhD
-
Malmö, Suecia, 20205
- Reclutamiento
- Department of Intensive Care, Skåne University Hospital
-
Contacto:
- Joachim P Düring, MD, PhD
- Número de teléfono: +46705917599
- Correo electrónico: joachim.during@med.lu.se
-
Contacto:
- Mia H Hylén, RN, PhD
- Correo electrónico: mia.hylen@skane.se
-
Investigador principal:
- Joachim P Düring, MD, PhD
-
Umeå, Suecia
- Reclutamiento
- Dep. of Intensive Care, Norrlands Universitets Sjukhus
-
Contacto:
- Matthias Schien
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Método de muestreo
Muestra no probabilística
Población de estudio
STEPCARE participants at PAINCARE-participating sites who are included under approved PAINCARE substudy procedures and have not withdrawn consent for use of study data according to parent-trial procedures.
PAINCARE participants may be included retrospectively or prospectively according to local approvals and substudy implementation.
Descripción
Inclusion Criteria:
- Out-of-hospital cardiac arrest
- Adult, age 18 years or older
- Spontaneous circulation without chest compressions for at least 20 minutes
- Comatose, defined as not obeying verbal commands
- Enrolled within 4 hours after return of spontaneous circulation
Exclusion Criteria:
- Restrictions or limitations of care
- On extracorporeal membrane oxygenation before randomization
- Pregnancy
- Previously randomized in the STEPCARE trial
- Trauma or hemorrhage as the presumed cause of arrest
- Suspected or confirmed intracranial hemorrhage
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
1
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
Comatose out-of-hospital cardiac arrest patients
Adult participants in the STEPCARE trial (NCT05564754) enrolled at PAINCARE-participating sites under approved PAINCARE substudy procedures and not withdrawn from use of study data according to parent-trial procedures.
PAINCARE inclusion may occur retrospectively or prospectively according to local approvals and substudy implementation.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative Time in Moderate or Severe Pain While Alive and in the ICU Through 168 Hours
Periodo de tiempo: From randomization through 168 hours, ICU discharge, or death, whichever occurs first
|
Cumulative time, in hours, spent in moderate or severe pain while alive and in the ICU from randomization through 168 hours, ICU discharge, or death, whichever occurs first.
Moderate or severe pain is defined as NRS >3, CPOT >2, or BPS >5.
Each scheduled assessment represents the worst pain intensity since the previous assessment and is assigned to the corresponding preceding interval.
|
From randomization through 168 hours, ICU discharge, or death, whichever occurs first
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Evaluable Alive-in-ICU Time Spent in Moderate or Severe Pain Through 168 Hours
Periodo de tiempo: From randomization through 168 hours, ICU discharge, or death, whichever occurs first
|
Proportion of evaluable alive-in-ICU time spent in moderate or severe pain during the primary 0- to 168-hour pain-burden window.
The proportion is calculated as cumulative evaluable time in moderate or severe pain divided by total evaluable alive-in-ICU time, excluding time after ICU discharge or death and excluding non-scorable and remaining missing scorable intervals.
|
From randomization through 168 hours, ICU discharge, or death, whichever occurs first
|
|
Delirium Burden Through 168 Hours
Periodo de tiempo: From randomization through 168 hours
|
Proportion of evaluable point-prevalence delirium assessments with delirium present among assessments recorded as delirium present or absent through 168 hours.
Delirium is assessed using the Confusion Assessment Method for the ICU or the Intensive Care Delirium Screening Checklist.
Assessments recorded as not assessable are reported separately and do not contribute to the denominator; assessments recorded as not done are reported as missing.
|
From randomization through 168 hours
|
|
Hours Alive and Free of Invasive Ventilatory Support Through Day 30
Periodo de tiempo: From randomization through day 30
|
Number of hours from randomization to day 30 during which the participant is alive and not receiving invasive ventilatory support.
Participants who die before day 30 are assigned zero hours alive and free of invasive ventilatory support.
|
From randomization through day 30
|
|
ICU-Free Days Alive Through Day 30
Periodo de tiempo: From randomization through day 30
|
Number of days from randomization to day 30 during which the participant is alive and discharged from the ICU.
Participants who die before day 30 are assigned zero ICU-free days.
|
From randomization through day 30
|
|
Moderate or Severe Pain at 1 Month
Periodo de tiempo: At 1 month
|
Moderate or severe pain at the 1-month follow-up assessment, defined as Numeric Rating Scale score greater than 3 for worst pain on movement during the preceding 24 hours.
|
At 1 month
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Moderate or Severe Pain at 6 Months
Periodo de tiempo: At 6 months
|
Moderate or severe pain at the 6-month follow-up assessment, defined as Numeric Rating Scale score greater than 3 for worst pain on movement during the preceding 24 hours.
|
At 6 months
|
|
Health-Related Quality of Life at 6 Months
Periodo de tiempo: At 6 months
|
Health-related quality of life at 6 months assessed using EQ-5D-5L.
For exploratory binary analyses, clinically relevant health-related quality-of-life problems are defined as at least one EQ-5D-5L dimension scored at level 3 or higher.
EQ-5D-5L dimension profiles and EQ VAS will also be summarized descriptively.
|
At 6 months
|
|
Mobilization During ICU Care
Periodo de tiempo: From randomization through 168 hours
|
Mobilization during ICU care categorized as ICU Mobility Scale greater than 1 versus 1 or lower.
|
From randomization through 168 hours
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Joachim P Düring, MD, PhD, Lunds Universitet, Institutionen för kliniska vetenskaper, Lund, Anesthesia and Intensive Care, Skåne University Hospital , Malmö, Sweden
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Niemela VH, Reinikainen M, Nielsen N, Bass F, Young P, Lilja G, Dankiewicz J, Hammond N, Hastbacka J, Levin H, Moseby-Knappe M, Saxena M, Tiainen M, Ceric A, Holgersson J, Kamp CB, Tirkkonen J, Oksanen T, Kaakinen T, Bendel S, During J, Lybeck A, Johnsson J, Unden J, Lundin A, Kahlin J, Grip J, Lotman E, Romundstad L, Seidel P, Stammet P, Graf T, Mengel A, Leithner C, Nee J, Druwe P, Ameloot K, Wise MP, McGuigan PJ, White J, Govier M, Maccaroni M, Ostermann M, Hopkins P, Proudfoot A, Handslip R, Pogson D, Jackson P, Nichol A, Haenggi M, Hilty MP, Iten M, Schrag C, Nafi M, Joannidis M, Robba C, Pellis T, Belohlavek J, Rob D, Arabi Y, Buabbas S, Yew Woon C, Aneman A, Stewart A, Arnott C, Ramanan M, Panwar R, Delaney A, Reade M, Venkatesh B, Navarra L, Crichton B, Knight D, Williams A, Friberg H, Cronberg T, Jakobsen JC, Skrifvars MB. Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation (MAP-CARE): A protocol for a randomized clinical trial. Acta Anaesthesiol Scand. 2025 Jul;69(6):e70040. doi: 10.1111/aas.70040.
- Holgersson J, Niemela V, Skrifvars MB, Kamp-Jorgensen C, Saxena M, Young P, Bass F, Dankiewicz J, Hammond N, Hastbacka J, Levin H, Lilja G, Moseby-Knappe M, Tiainen M, Reinikainen M, Ceric A, During J, Lybeck A, Rodriguez-Santos D, Johnsson J, Unden J, Lundin A, Kahlin J, Grip J, Rosell J, Lotman EM, Navarra L, Crichton B, Knight D, Williams A, Romundstad L, Seidel P, Stammet P, Graf T, Mengel A, Leithner C, Nee J, Druwe P, Ameloot K, Wise M, Riddel J, Ahmed M, Buckel M, Mc Guigan P, Maharaj R, Wyncoll D, Thomas M, White J, Keeble TR, Pogson D, Nichol A, Haenggi M, Hilty MP, Iten M, Schrag C, Nafi M, Joannidis M, Robba C, Pellis T, Belohlavek J, Smid O, Rob D, Arabi Y, Buabbas S, Yew Woon C, Aneman A, Stewart A, Bernard S, Palmer-Simpson C, Simpson N, Ramanan M, Reade M, Delaney A, Venkatesh B, Tirkkonen J, Oksanen T, Kaakinen T, Bendel S, Friberg H, Cronberg T, Jakobsen J, Nielsen N. Fever management with or without a temperature control device after out-of-hospital cardiac arrest and resuscitation (TEMP-CARE): A study protocol for a randomized clinical trial. Acta Anaesthesiol Scand. 2025 May;69(5):e70034. doi: 10.1111/aas.70034.
- Ceric A, Dankiewicz J, Hastbacka J, Young P, Niemela VH, Bass F, Skrifvars MB, Hammond N, Saxena M, Levin H, Lilja G, Moseby-Knappe M, Tiainen M, Reinikainen M, Holgersson J, Kamp CB, Wise MP, McGuigan PJ, White J, Sweet K, Keeble TR, Glover G, Hopkins P, Remmington C, Cole JM, Gorgoraptis N, Pogson DG, Jackson P, During J, Lybeck A, Johnsson J, Unden J, Lundin A, Kahlin J, Grip J, Lotman EM, Romundstad L, Seidel P, Stammet P, Graf T, Mengel A, Leithner C, Nee J, Druwe P, Ameloot K, Nichol A, Haenggi M, Hilty MP, Iten M, Schrag C, Nafi M, Joannidis M, Robba C, Pellis T, Belohlavek J, Rob D, Arabi YM, Buabbas S, Yew Woon C, Aneman A, Stewart A, Reade M, Delcourt C, Delaney A, Ramanan M, Venkatesh B, Navarra L, Crichton B, Williams A, Knight D, Tirkkonen J, Oksanen T, Kaakinen T, Bendel S, Friberg H, Cronberg T, Jakobsen JC, Nielsen N. Continuous deep sedation versus minimal sedation after cardiac arrest and resuscitation (SED-CARE): A protocol for a randomized clinical trial. Acta Anaesthesiol Scand. 2025 May;69(5):e70022. doi: 10.1111/aas.70022.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
15 de octubre de 2023
Finalización primaria (Estimado)
Finalización primaria
19 de mayo de 2026
Finalización del estudio (Estimado)
Finalización del estudio
31 de octubre de 2028
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
27 de abril de 2026
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
27 de abril de 2026
Publicado por primera vez (Actual)
Publicado por primera vez
4 de mayo de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
14 de mayo de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
11 de mayo de 2026
Última verificación
Última verificación
1 de mayo de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Enfermedades cardiovasculares
- Desordenes mentales
- Enfermedades cardíacas
- Confusión
- Manifestaciones neuroconductuales
- Trastornos neurocognitivos
- Paro cardíaco
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor
- Delirio
- Paro cardíaco fuera del hospital
Otros números de identificación del estudio
Otros números de identificación del estudio
- STEPCARE_PAINCARE
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Descripción del plan IPD
Upon reasonable request to Principal investigator after publication of the STEPCARE and PAINCARE studies
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .